Requintosa, Mary Aphfe .
HRN: 26-56-52 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/25/2025
CLINDAMYCIN 300MG (CAP)
03/25/2025
04/01/2025
ORAL
300mg
TID
S/P Endometrial Biopsy
Waiting Final Action
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes